BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250303
DTEND;VALUE=DATE:20250306
DTSTAMP:20260515T103810
CREATED:20241008T141820Z
LAST-MODIFIED:20241008T141820Z
UID:39880-1740960000-1741219199@www.pharmajournalist.com
SUMMARY:10th Annual Innate Killer Summit
DESCRIPTION:2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data\, expansion into autoimmune disease\, and combination approaches all take off! So\, we are proud to announce the 10th Anniversary Innate Killer Summit returning to San Diego this March\, to showcase all the above and much more. \nCarefully compiled alongside industry experts from Artiva Biotherapeutics\, Immunity Bio\, INmune Bio and UCL (just to name a few!)\, our agenda will provide you with the latest clinical data in NK cells\, engagers\, cytokines and more\, to revolutionize and accelerate innate therapies once again. \nAnd that’s not all! Owing to the overwhelming excitement\, in 2025 we will introduce a *BRAND-NEW* Applications of NK Biology to Autoimmunity Focus Day\, alongside critical workshops exploring cryopreservation and donor selection\, to provide your company with the NK insights needed to pave your future in innate immunity treatment. \nSecure your place to join us in celebrating a decade of uniting longstanding pioneers and trailblazers in the NK space! \nTo know more visit: https://ter.li/fqxr57
URL:http://www.pharmajournalist.com/event/10th-annual-innate-killer-summit/
LOCATION:DoubleTree by Hilton – San Diego Mission Valley\, 7450 Hazard Center Drive\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250303
DTEND;VALUE=DATE:20250307
DTSTAMP:20260515T103810
CREATED:20241128T113542Z
LAST-MODIFIED:20241128T113542Z
UID:40201-1740960000-1741305599@www.pharmajournalist.com
SUMMARY:15th World ADC London Summit 2025
DESCRIPTION:Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval\, the field has seen a surge in multi-billion-dollar acquisitions\, commercialisation deals\, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments and expand their use to wider patient populations. \nReturning for its 15th anniversary year\, World ADC London is the leading European conference uniting over 1000 ADC enthusiasts to maximise the therapeutic index of ADCs. Whether you are brand new to the field or have over a decade of experience\, work in discovery or manufacturing\, hold a strategic position or work day-to-day in the lab\, this meeting offers something for you! \nTake a look at the full agenda here. \nEmbark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation\, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle. \nHere are some of the leading minds sharing translatable lessons to advance your pipeline including: \n\nAlireza Tafazzol\, Senior Scientist II\, Oncology Bioinformatics\, AbbVie.\nOsama Chahrour\, Principal Scientist\, Chemical Development\, AstraZeneca.\nYu-Shin Hsu\, Research Analyst\, Independent.\nJinwon Jung\, Senior Director\, Protein Engineering\, ABL Bio.\nHayley Jackman\, Director\, CMC Regulatory Affairs\, AstraZeneca.\nLolke de Haan\, Vice President\, Toxicology\, ADC Therapeutics.\nMax Lee\, Associate Director\, AstraZeneca.\nPaul WolstenholmeHogg\, Vice President\, Medicinal Chemistry\, ADC Therapeutics.\nTomohiro Fujii\, ADC Researcher\, Ajinomoto Bio-Pharma Services.\nYing Buechler\, Chief Technology Officer\, Ambrx\, a Johnson & Johnson Company.\nPaul Jaminet\, Chief Executive Officer\, Angiex.\nUchechukwu OkorjiObike\, Senior Scientist\, Bioassay Development\, AstraZeneca.\n\nSee the full speaker faculty and session details here. \nDon’t miss this chance to unlock unmissable R&D\, focused industry networking opportunities\, and emerging trends taking hold of the ADC field with sessions from 120+ world-leading speakers including Daiichi Sankyo\, AstraZeneca\, Pfizer\, AbbVie\, Merck\, GSK\, Johnson & Johnson\, ADC Therapeutics and more.
URL:http://www.pharmajournalist.com/event/15th-world-adc-london-summit-2025/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250311
DTEND;VALUE=DATE:20250314
DTSTAMP:20260515T103810
CREATED:20241111T113610Z
LAST-MODIFIED:20241114T113531Z
UID:40065-1741651200-1741910399@www.pharmajournalist.com
SUMMARY:4th Cell Therapy Potency Assay Summit
DESCRIPTION:In the current cell therapy landscape\, where funding is tight and clinical development a priority\, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency Assay Summit\, uniting AD\, QC and regulatory experts\, this summit works to design potency assays that not only conform to changing guidelines but also streamline patient access to the next generation of cell therapies. \nJoin leading organizations like Arsenal Biosciences\, BlueRock Therapeutics\, the NIST and Vertex Pharmaceuticals\, as they share development strategies and the latest technologies needed to streamline your assay development workflows. You won’t want to miss out! \nTo know more visit: https://ter.li/inqax5
URL:http://www.pharmajournalist.com/event/4th-cell-therapy-potency-assay-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250311
DTEND;VALUE=DATE:20250314
DTSTAMP:20260515T103810
CREATED:20250211T125459Z
LAST-MODIFIED:20250211T125459Z
UID:40474-1741651200-1741910399@www.pharmajournalist.com
SUMMARY:6th Supply Chain & Logistics for Cell & Gene Therapies Summit
DESCRIPTION:The 6th Supply Chain & Logistics for Cell & Gene Therapies Summit is the ultimate practical guide for designing scalable\, traceable\, and resilient global supply chains to support the growing number of complex cell and gene therapies. It is an industry wide challenge and vital part of development\, to ensure safe and timely delivery to patients. This relies on robust global supply chains. \nThe 2025 summit will provide a comprehensive deep dive into end-to-end global supply chains for cell and gene therapies\, covering autologous\, allogeneic\, in vivo\, and ex vivo programs. This is the industry’s premier platform to hear from more than 20 leading voices spanning clinical and commercial drug developers\, trusted service providers\, and clinical experts who will be sharing solution-driven case studies. These will focus on key areas such as defining robust processes\, securing reliable material supplies\, implementing digital solutions\, and ensuring seamless traceability of chain of identity and custody throughout the cold chain. \nOur 90+ attendees will gain invaluable and actionable insights on how to become commercial-ready\, expand globally\, and enhance cross-functional collaboration. The summit will unite professionals from Supply Chain\, Logistics\, Sourcing\, Quality\, and Operations sectors\, who will share best practices in supply planning\, manufacturing\, packaging\, labeling\, and delivery. Together\, they will brainstorm practical solutions for an integrated approach that strengthens value chains. \nFor those planning or executing a scaled\, integrated CGT supply chain\, this summit provides a unique opportunity to innovate and address the logistical and operational challenges currently facing the industry. As the industry’s premier networking and knowledge-based event dedicated to optimizing cell and gene therapy supply chains\, you don’t miss out on this opportunity to network\, learn\, and collaborate with experts in the field. \nTo learn more about who will be attending including those from Novartis\, Beam Therapeutics\, Astellas Gene Therapies\, and more – download the event guide now. \nTo know more visit: https://ter.li/yjybt6
URL:http://www.pharmajournalist.com/event/6th-supply-chain-logistics-for-cell-gene-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250321
DTSTAMP:20260515T103810
CREATED:20241107T144640Z
LAST-MODIFIED:20241107T144640Z
UID:40031-1742256000-1742515199@www.pharmajournalist.com
SUMMARY:The 5th Operationalize: Expanded Access Programs Summit
DESCRIPTION:Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However\, challenges persist\, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access\, managing global supply chains\, importation\, licensing\, and labeling standards remains a critical focus for ensuring patients worldwide receive the treatments they need. \nJoin over 120 thought leaders from Access\, Medical Affairs\, Clinical Operations\, and Clinical Supply for an unparalleled opportunity to network\, exchange insights\, and explore innovative strategies for overcoming the regulatory and operational hurdles that complicate global access to life-saving therapies. \nAt this year’s summit\, you’ll gain actionable insights on successfully planning and executing Post-Trial Access Programs\, navigating the regulatory landscapes of the US\, LATAM\, Europe\, and South & East Asia\, and developing compliant\, effective global access strategies. You’ll also explore best practices for creating exit plans and transition strategies that address hurdles in reimbursement\, off-request processes\, and country-specific regulations—plus so much more! \nTo know more visit: https://ter.li/org1vd
URL:http://www.pharmajournalist.com/event/the-5th-operationalize-expanded-access-programs-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250321
DTSTAMP:20260515T103810
CREATED:20250127T202012Z
LAST-MODIFIED:20250127T202012Z
UID:40377-1742256000-1742515199@www.pharmajournalist.com
SUMMARY:5th Wet AMD Diabetic Eye Disease Drug Summit
DESCRIPTION:With Merck’s acquisition of EyeBio for $1.3 Billion\, Roche’s Vabysmo launch success and multiple other phase II and III trials in DME\, DR\, RVO\, and Wet AMD\, there is plenty to discuss in the retinal vascular drug space as drug developers seek to new alternatives to anti-VEGF\, explore biosimilars\, and target retinal fibrosis and more to find truly transformative drugs for patients. \n \nThe 2025 Wet AMD & Diabetic Eye Disease Summit is set to be an essential meeting for industry leaders\, research innovators\, and clinical experts dedicated to transforming the landscape of retinal vascular disease treatments. \nWhat’s New for the 2025 Wet AMD & Diabetic Eye Disease Drug Summit? \n\nNew Strategies for Retinal Vascular Drug Clinical Trials: Delve into advanced strategies for designing clinical trials in Wet AMD and diabetic eye disease\, focusing on patient-specific factors and adaptive trial models with insights from Bayer and Aviceda Therapeutics\nEmerging Biomarker Approaches Wet AMD\, DR. DME & RVO: Explore the critical role of biomarkers and clinical endpoints in developing therapies for neovascular retinal disorders\, featuring discussions from Opus Genetics and Ocugen\nInnovative Oral Anti-Inflammatory Treatments for Diabetic Eye Disease: Discover how InflammX Therapeutics is addressing the unmet need in DR and DME patients non-responsive to anti-VEGF therapy with their once-daily oral small molecule\nAdvancements in Retinal Drug Delivery: Discover the benefits of suprachoroidal TKI delivery for Wet AMD with Clearside Biomedical\, and hear from Sanofi about incorporating drug delivery devices to improve physician efficiency and patient compliance\nBreakthroughs in Wet AMD Gene Therapy: Learn about emerging gene therapies for Wet AMD\, focusing on innovative approaches and potential impact on patient care with HuidaGene Therapeutics Doheny Eye Centers\n\nJoin 50+ biopharma experts from clinical\, medical\, regulatory. value and access departments from Bayer\, Sanofi\, EyePoint\, Ocular Therapeutix\, Clearside Biomedical\, RevOpsis\, Opus Genetics\, and HuidaGene Therapeutics as they accelerate towards releasing longer-lasting\, non-invasive and more effective drugs for retinal disease patients. \nTo know more visit: https://ter.li/sew767
URL:http://www.pharmajournalist.com/event/5th-wet-amd-diabetic-eye-disease-drug-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T103810
CREATED:20241127T122738Z
LAST-MODIFIED:20241127T122738Z
UID:40140-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:4th Novel Conjugate Summit
DESCRIPTION:The field of conjugatable drugs is advancing at a rapid pace\, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals\, which paves the way towards a new generation of more targeted\, safer and efficacious novel conjugated drugs. \nThe 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in bioconjugates. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates\, join us to delve into each of their value propositions and navigate crucial considerations like target selection\, PK/PD profiles\, and translation into the clinic. \nConnect with 100+ experts from big pharma\, cutting-edge biotechs and conjugation and manufacturing providers\, all sharing crucial insights on striking success with new formats and payloads. \nNow is the time to expand your conjugate design toolkit to pursue emerging cancer targets and stay ahead in the race to deliver safer\, more targeted therapies beyond traditional ADCs Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025!
URL:http://www.pharmajournalist.com/event/4th-novel-conjugate-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T103810
CREATED:20241127T125100Z
LAST-MODIFIED:20241127T125100Z
UID:40163-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:8th Gene Therapy Development Summit
DESCRIPTION:With 14 new gene therapy approvals in the last 18 months\, billion-dollar collaborations\, and the development of treatments for more common conditions\, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases. \nReturning to Boston in March\, the 8th Gene Therapy Development Summit\, formerly known as the Gene Therapy for Rare Disorders Summit\, will unite 200+ gene therapy experts to tackle the field’s biggest challenges of achieving genuine scalability and accessibility to meet growing patient demand. \nFor the first time\, this industry-defining meeting will reflect the field’s growing focus on developing therapies for common diseases\, whilst addressing existing hurdles in rare and ultra-rare disorders. This is your unparalleled opportunity to delve into: \n\nThe latest global regulatory requirements\nOptimizing routes for CNS\nOcular and inner ear disorders\nInnovations in capsid engineering and dosing strategies\nIncreasing volumetric productivity to reduce CoGs\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/8th-gene-therapy-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T103810
CREATED:20241212T121823Z
LAST-MODIFIED:20241212T121823Z
UID:40241-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:2nd Biophysics for Drug Discovery Summit
DESCRIPTION:In today’s complex drug development landscape\, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through the drug development pipeline. The 2nd Biophysics for Drug Discovery Summit is your exclusive opportunity to unite and network with your biophysics and drug discovery peers and delve into the application of biophysical techniques including SPR\, NMR\, Thermal shift assays\, mass spec\, and the emerging technologies\, across modalities and targets to inform efficient drug discovery. \n \nThe Biophysics for Drug Discovery Summit will delve into the latest in strategy and application of biophysical techniques across novel targets and modalities\, from AI-driven drug discovery to fragment-based drug discovery\, and in-cell biophysics to single-particle tracking. By understanding the intricate molecular mechanisms and improving hit selection and target identification\, we can accelerate the discovery of innovative therapies and improve the effectiveness and efficiency of drug development. \nUnlock the future of therapeutics through biophysics and keep up to date as field evolves into new technologies and applications\, this meeting will provide you with thought-provoking insights on biophysics applications to take away to your wider drug discovery teams. Join the Biophysics for Drug Discovery Summit in March 2025 and build meaningful connections with 70+ biophysicists and drug discovery experts and move the field forward with unique insights and deep-dive conversations. \nTo know more visit: https://ter.li/8u0s3n
URL:http://www.pharmajournalist.com/event/2nd-biophysics-for-drug-discovery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T103810
CREATED:20250116T124349Z
LAST-MODIFIED:20250116T124349Z
UID:40335-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:2nd EHS for Biopharma Summit East
DESCRIPTION:As the biopharma industry evolves with rapid advancements in drug development\, manufacturing\, and research\, EHS leaders are tasked with safeguarding employee health\, maintaining a culture of safety\, and addressing environmental concerns. Navigating these challenges while meeting sustainability goals and mitigating risks has become essential for operational success. EHS professionals must continuously adapt to this dynamic landscape to protect their most valuable asset: their workforce. \nThe 2nd EHS for Biopharma East Summit is an essential event for EHS professionals working in the biopharma industry\, focused on overcoming the sector’s unique regulatory and operational challenges. With over 100+ attendees\, this summit will provide valuable insights on navigating evolving regulations\, optimizing safety protocols\, and enhancing environmental stewardship. Whether your goal is to strengthen safety culture\, reduce incidents\, or achieve sustainability targets\, the summit offers the tools\, knowledge\, and networking opportunities necessary to elevate EHS practices. \nWhat can you expect? – Your Definitive Guide to EHS for Biopharma \n\nDiscover actionable strategies for managing global EHS challenges with insights from Astellas\, MilliporeSigma\, and Elanco\nEnhance safety culture in laboratory and manufacturing settings with guidance from AstraZeneca\, Texcell\, and Cytovance\nLearn best practices for embedding EHS programs within the workforce\, fostering leadership buy-in\, employee engagement\, and promoting psychological well-being to minimize burnout\nExplore the latest technologies driving EHS excellence with expertise from AstraZeneca and Sanofi\nConnect with industry peers to network and benchmark best practices.\nEarn continuing education credits from BCSP\, ABSA\, and CIH\n\nCreated for EHS professionals spanning EHS directors\, EHS managers and EHS technical experts focused on workplace safety\, environmental compliance\, and operational excellence. \nJoin us this March \nFind out more here \nRegister your place
URL:http://www.pharmajournalist.com/event/2nd-ehs-for-biopharma-summit-east/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T103810
CREATED:20250123T121746Z
LAST-MODIFIED:20250123T121746Z
UID:40347-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:7th Treg-Directed Therapies Summit
DESCRIPTION:Over the past year\, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca\, and Parvus and AbbVie\, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have long lacked effective solutions and are the future of precision medicine in autoimmune and inflammatory diseases. \n \nThe 7th Treg-Directed Therapies Summit is your premier event dedicated to exploring and overcoming the unique challenges and advancements specific to Treg. Offering you exclusive access to the latest industry insights\, clinical data\, Treg biology breakthroughs and strategies for advancing therapies to the clinic from trailblazing companies and academic leaders\, including Abata Therapeutics\, Harvard Medical School\, Nektar Therapeutics\, Parvus Therapeutics\, PolTreg\, ThyTech and many more! \nWhether you are in discovery\, navigating the complexities of IND filings\, or transitioning to the clinic\, this forum provides an unparalleled opportunity to engage with leaders at the forefront of cell therapy and modulator innovation. Connect with senior experts in cell therapy manufacturing and modulator production\, build strategic relationships with investors\, pharmaceutical companies and academics\, opening doors to future collaborations and partnership opportunities. \nEvent guide link: https://ter.li/adqtg1
URL:http://www.pharmajournalist.com/event/7th-treg-directed-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250326
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T103810
CREATED:20250206T124811Z
LAST-MODIFIED:20250206T124811Z
UID:40435-1742947200-1743119999@www.pharmajournalist.com
SUMMARY:2nd DNA Process Development & Manufacturing Summit
DESCRIPTION:The 2nd DNA Process Development & Manufacturing Summit: Accelerating Innovative Advanced Therapies with Revolutionary Plasmid & Enzymatic DNA. \nWith the plasmid DNA manufacturing market set to rise to $39.3Bn by 2033\, and the demand for advanced therapies continuing to surge as gene therapy reaches new heights and DNA vaccines promise to transform outbreak response\, there has never been a more crucial time to revolutionize the production of high-quality DNA as a starting material and API. \nThe 2nd DNA Process Development & Manufacturing Summit 2025 returns as the world’s only industry-dedicated technical forum focused on optimizing process development for plasmid and cell-free DNA\, adhering to regulatory requirements to streamline IND approvals for advanced therapies\, and developing scalable\, efficient manufacturing solutions.\nIndustry experts from the likes of Pfizer\, Sanofi\, Novartis\, Beam Therapeutics\, Moderna\, Merck and Chroma Medicine are uniting to share innovations in plasmid design\, advances off-the-shelf lysis equipment and purification techniques\, and strategies to support timely\, cost-efficient large-scale DNA production. \nFind out more: https://ter.li/7k68s7
URL:http://www.pharmajournalist.com/event/2nd-dna-process-development-manufacturing-summit/
LOCATION:The Hyatt Regency\, 1 Ave de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR